1SIMONS MP,NAUSEEF WM,GRIFFITH TS.Neutrophils and TRAIL: insights into BCG immunotherapy for bladder cancer[J].Immunol Res,2007,39(1-3):79-93.
2ROSSI R,LICHTNER M,IORI F,et al.Dendritic cells in blood and urine samples from bladder cancer patients undergoing BCG immunotherapy[J].Arch Ital Urol Androl,2013,85(4):157-163.
3VAN DER HORST G,BOS L,VAN DER PLUIJM G.Epithelial plasticity,cancer stem cells,and the tumor-supportive stroma in bladder carcinoma[J].Mol cancer Res,2012,10(8):995-1009.
4ZHU Z,SHEN Z,XU C.Inflammatory pathways as promising targets to increase chemotherapy response in bladder cancer[J].Mediators Inflamm,2012,110:528690.
5GABRILOVICH DI,NAGARAJ S.Myeloid-derived suppressor cells as regulators of the immune system[J].Nat Rev Immunol,2009,9(3):162-174.
6ERUSLANOV E,NEUBERGER M,DAURKIN I,et al.Circulating and tumor-infiltrating myeloid cell subsets in patients with bladder cancer[J].Int J cancer,2012,130(5):1109-1119.
7ROBINSON BD,SICA GL,LIU YF,et al.Tumor microenvironment of metastasis in human breast carcinoma: a potential prognostic marker linked to hematogenous dissemination[J].Clin Cancer Res,2009,15(7):2433-2441.
8RODRIGUEZ PC,ERNSTOFF MS,HERNANDEZ C,et al.Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes[J].Cancer Res,2009,69(4):1553-1560.
9MANTOVANI A,LOCATI M.Tumor-associated macrophages as a paradigm of macrophage plasticity,diversity,and polarization: lessons and open questions[J].Arterioscler Thromb Vasc Biol,2013,33(7):1478-1483.
10MANTOVANI A,SICA A,SOZZANI S,et al.The chemokine system in diverse forms of macrophage activation and polarization[J].Trends Immunol,2004,12(12): 677-686.
2Maringwa JT, Quinten C, King M, et al. Minimal important differences for interpreting health-relatedquality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trials[J]. Support Care Cancer, 2011, 19(11): 1753- 1760.
3Bhattacharya A, Li Y, Shi Y, et al. Enhanced inhibi- tionof urinary bladder cancer growth and muscle invasion by allylisothiocyanate and celecoxib in combination [J]. Carcinogenesis, 2013, 34(11): 2593-2599.
4Srivastava A K , Singh PK, Singh D , et al. Evaluation of urinary XIAPas a diag - nostic biomarker of carcinoma of urinary bladder [J] . TumorBiol, 2 0 1 4 ,3 5 (8 ) : 8243 -8 2 4 8 .
5Ham W S, Kim WT, Jeon H J, et al. Long - term outcome of sim ultaneoustransurethral resection of bladder tumor and prostate in patientswith non - muscle invasive bladder tumor and bladder outlet obstruction[J] , JU ro l, 2 0 0 9 ,1 8 1 (0 4 ) : 1594 - 1599.
6Ebbing J, Mathia S, Seibert FS, et al. Urinary calprotectin: a new dia- gnostic marker in urothelial carcinoma of the bladder [J] . World JUrol, 2 0 1 4 ,3 2 (6 ) : 1485 -1 4 9 2 .
7Zhao C , Kim MK, Kim H J, et al. Comparative safety analysis of surgicalsmoke from transurethral resection of the bladder tumors and trans -urethral resection of the p rostate[J]. Urology, 2 0 1 3 ,8 2 (3 ) :744.
